Lack of Detectable Human Immunodeficiency Virus Type 1 Superinfection during 1072 Person‐Years of Observation
Open Access
- 1 August 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 188 (3), 397-405
- https://doi.org/10.1086/376534
Abstract
We examined consecutive protease (PR) and reverse transcriptase (RT) sequences from human immunodeficiency virus (HIV) type 1-infected individuals, tKeywords
This publication has 18 references indexed in Scilit:
- Intersubtype Human Immunodeficiency Virus Type 1 Superinfection following Seroconversion to Primary Infection in Two Injection Drug UsersJournal of Virology, 2002
- Evolution of Primary Protease Inhibitor Resistance Mutations during Protease Inhibitor Salvage TherapyAntimicrobial Agents and Chemotherapy, 2002
- Human Immunodeficiency Virus Type 1 Reverse‐Transcriptase and Protease Subtypes: Classification, Amino Acid Mutation Patterns, and Prevalence in a Northern California Clinic‐Based PopulationThe Journal of Infectious Diseases, 2001
- High Degree of Interlaboratory Reproducibility of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Sequencing of Plasma Samples from Heavily Treated PatientsJournal of Clinical Microbiology, 2001
- Very Young Gay and Bisexual Men Are at Risk for HIV Infection: The San Francisco Bay Area Young Men's Survey IIJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Antiretroviral Drug Resistance Testing in Adult HIV-1 InfectionJAMA, 2000
- Gender differences in HIV-1 diversity at time of infectionNature Medicine, 2000
- Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispeciesMicrobiology, 2000
- Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotypeAIDS, 1999
- Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapyProceedings of the National Academy of Sciences, 1998